Abstract:e21100 Background: Despite that the biomarkers of single mutational events predicting efficacy of immune checkpoint inhibitors (ICIs) have been intensively studied in non-squamous NSCLC, the interaction effects between mutations on prediction were scarcely investigated due to the limited sample size. Deeper understanding of these inter-relations could optimize the prediction model and provide insights for basic research on anti-tumor immunity. Methods: In total, 1083 patients with non-squamous NSCLC were included. 288 patients with both PFS and OS data receiving monotherapy from the MSKCC, DFCI, and SNCC cohorts were included in the training set-1. 304 and 294 patients from the POPLAR/OAK cohort treated with atezolizumab or docetaxel were included in the training set-2 and the control set respectively. Validation set-1 and validation set-2 respectively consists of 104 patients receiving monotherapy with only OS data and 93 patients treated with combination therapy from the MSKCC cohort. Risk models using single mutations (uni-model) and both single mutations and interactions (inter-model) were developed via multivariable Cox proportional hazards regression model. Results: By cross-validation in training set-1/2, five single mutational events, including mutations of EGFR, STK11, PTPRD, members in PI3K pathway, and members in HRR pathway, and five interactions ( EGFR* PI3K pathway, TP53* KRAS, TP53* ERBB4, cell cycle pathway*HRR pathway, and PI3K pathway*chromatin remodeling pathway) were identified as predictive biomarkers. The score of inter-model exhibited higher correlation with immunotherapeutic PFS in the training sets, compared to the uni-model ( Dxy: 0.173 vs. 0.139). Uni-score low was moderately associated with longer OS in the validation set-1 (HR = 0.62, 95% CI 0.35-1.08, P = 0.092), and PFS in the validation set-2 (HR = 0.32, 95% CI 0.18-0.60, P < 0.001). Inter-score low showed better predictive utility in the validation set-1 (HR = 0.53, 95% CI 0.30-0.94, P = 0.030), and the validation set-2 (HR = 0.23, 95% CI 0.10-0.50, P < 0.001). On the contrary, inter-score low was associated with worse PFS and OS in the control set, indicating that inter-score low might be a negative prognostic biomarker, but positive predictive biomarker to efficacious immunotherapy. Conclusions: Our study suggests that the predictive biomarkers might not be similarly predictive in every single subpopulation, and they might be merely valid under certain circumstances, which is termed by “interaction effect”. Given this, the future researches probing into immunotherapeutic predictor should focus on the mutual influence between distinct biomarkers, for instance, adding an interaction term in the Cox proportional hazards regression model.

SMO Mutation Predicts the Effect of Immune Checkpoint Inhibitor: from NSCLC to Multiple Cancers.

Associations Between Interaction Effects of Mutational Events and Efficient Immunotherapy in Squamous NSCLC: Results from 373 Patients.

P2.03-35 Non-Small-Cell Lung Cancer with SMO Gene Variants of Uncertain Significance Share Distinct Molecular Features

SMOX expression predicts the prognosis of non-small cell lung cancer

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC

MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC

A Mutation-Based Gene Set Predicts Survival Benefit after Immunotherapy Across Multiple Cancers and Reveals the Immune Response Landscape

JCSE01.23 Specific TP53 Mutation Subtypes As Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma

The Immune Response-Related Mutational Signatures and Driver Genes in Non-Small-cell Lung Cancer

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer

B Cell Receptor Signaling Pathway Mutation As Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

PAPPA2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC and SKCM.

Interaction effect between mutational events on predicting efficacious immunotherapy in nonsquamous NSCLC: Results from 1,083 patients.

Supplementary Figures from SWI/SNF Complex Genomic Alterations As a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers

PAPPA2 Mutation As a Novel Indicator Stratifying Beneficiaries of Immune Checkpoint Inhibitors in Skin Cutaneous Melanoma and Non‐small Cell Lung Cancer

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC

Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer